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MicroAbstract 
Imatinib has been the standard of care in chronic myelogenous leukemia for fifteen years. Its 
optimal plasma concentration correlates with optimal disease response. We compared 
plasma concentrations in patients who switched from branded to generic imatinib. No 
statistical difference in achieved imatinib plasma concentrations was found, and the 
treatment response was maintained.  
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Abstract 
Introduction: For over a decade, imatinib has been the first-line treatment of Philadelphia 
chromosome-positive chronic myeloid leukemia (CML). Doubts on the bioequivalence and 
bioavailability of emerging generic compounds have been expressed. Adequate imatinib 
plasma concentration (IPC ≥1000 µmol/L) is associated with a better chance of optimal 
treatment response in CML. In this study we compared the achieved IPCs between the 
branded compound and its two generic forms. Patients and methods: IPCs were compared 
in 24 consecutive CML patients in first chronic phase who changed from branded to generic 
imatinib. The median age was 49 (22–76) years. Fifteen of them were male. Six patients 
were switched to Neopax, 13 to Imakrebin, and 5 patients received both generics 
consecutively. All compounds were used in an equivalent dose of 400 mg per os once daily 
for at least one month before plasma concentrations were measured. High-performance 
liquid chromatography was used to determine imatinib plasma concentration from a 
specimen collected 21–24 hours after the last dose. Results: Median IPC achieved with 
branded imatinib was 1454 µmol/L (range 485-2707) with 18 patients (75%) having IPC ≥ 
1000 µmol/L. For Neopax and Imakrebin, median IPCs were 1717 (1249-3630) and 1458 
(707-880) respectively with 11/11 (100%) and 16/18 (89%) patients having IPC ≥ 1000 
µmol/L. No significant difference in measured IPCs between all three compounds was found 
(p>0.257). Conclusion: When taken at equivalent doses, imatinib generics are bioequivalent 
and comparable in clinical efficacy and have the potential for substantial savings in CML 
treatment cost. 
 
 
Keywords: imatinib mesylate, chronic myelogenous leukemia, therapeutic drug monitoring, 
generics  
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Introduction 
Since 2001, imatinib improved prognosis in chronic myelogenous leukemia (CML)1 and is the 
standard of care worldwide. Recently, imatinib generics became available. Some case 
reports/series2–6 raised concerns about its efficacy but refer to generics with questionable 
bioequivalence.7 To date, there is no evidence that imatinib generics approved in North 
America and the European Union (EU) lack efficacy compared to the branded drug, even 
when comparing different imatinib crystal forms.7 
Several studies correlated imatinib plasma concentrations (IPC) with adequate treatment 
response.8–10 Recommended therapeutic imatinib plasma concentration (IPC) is between 
1000 µmol/L and 3000 µmol/L. Small intra-patient variations, greater inter-patient variation, 
proportional dose-exposure relationship, and therapeutic concentration interval are basic 
imatinib properties making it suitable for therapeutic drug monitoring (TDM).11 Our institution 
standard operating protocol does not require regular screening IPC monitoring except in 
cases of unmet optimal treatment goal at respective time points according to ELN criteria.12 
After the branded imatinib patent had expired in March 2013 (before Croatia was admitted to 
the EU), Neopax (later on marketed as Meaxin, Krka d.d., Slovenia) and Imakrebin (Alvogen 
IPCo S.ar.l., Luxembourg) became available on the Croatian market as the first two generics. 
According to the Croatian Institute for Health Insurance reimbursement policy, generics were 
instituted as the first line of treatment in newly diagnosed and those already using branded 
imatinib (Glivec, Novartis AG, Switzerland). Motivated by controversies on the efficacy of 
imatinib generics, we’ve conducted a trial in measuring IPCs in patients changing from 
branded to a generic drug. Results of comparison of IPCs achieved with branded and 
generic imatinibs are presented here as a unicentric experience. 
 
Patients and Methods 
Study design 
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IPC was measured in 24 consecutive CML patients in their first chronic phase running out 
their last branded imatinib prescription. Their prescriptions were refilled with one of the 
available generics by our institution pharmacy. Afterward, branded imatinib was changed to 
one of the available generics or both consecutively. IPCs were measured every time the 
change in prescription was made. All drugs were used in an equivalent dose of 400 mg po qd 
for at least one month before IPCs were measured. Patients were interviewed for adherence 
to regular imatinib use. During the study, no relevant changes in other chronic therapy were 
recorded. 
Blood sampling and analytical methods 
High-performance liquid chromatography (HPLC) was used to determine imatinib plasma 
concentration from a peripheral blood specimen collected 21–24 hours after the last dose. 
The test was performed without delay or pooling the samples. Imatinib was extracted from 
plasma with methanol. Clozapine was used as an internal standard. The sample was 
fractionated on a column MN EC Nucleosil 100-5-C-18 EC 250 x 4.6 mm with a mobile 
system consisting of ammonium acetate buffer, methanol, and acetonitrile (40:40:20). The 
flow rate was 0.75 ml min-1. Quantitation was performed by measurement of UV detector at 
the wavelength of 265 nm. 
The bcr-abl1 level in peripheral blood was quantified after at least one month of the use of a 
different drug compound. A quantitative real-time polymerase chain reaction was performed 
using a commercial Ipsogen BCR-ABL1 Mbcr kit (Qiagen, Germany). Reporting was done on 
an international scale, according to ELN standards.13  
Statistical methods 
Descriptive statistics (mean, median, range, and proportions) were calculated to provide 
group characteristics. A paired samples t-test was done to test the significance of the means 
between two groups, Kruskal-Wallis’s test was used to compare continuous non-parametric 
variables, and Fisher’s exact test was used in comparing the proportions between the 
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groups. A two-tailed p-value of <0.05 was considered as statistically significant. All analyzes 
were performed using IBM SPSS Statistics version 20 (IBM Corp., Armonk, NY). 
 
Results 
Study population characteristics 
Twenty-four patients who changed from branded imatinib to generics with a median age of 
49 years (range 22–76) were enrolled in the trial. Fifteen of them (63%) were male. Branded 
imatinib was changed to Neopax (11 patients), or Imakrebin, either from Glivec or Neopax, at 
some time point (18 patients). There were no statistical differences between the patients 
using corresponding imatinib when grouped by gender (p=0.935), age (p=0.698), or 
adherence (p=0.166). The analysis was also done for the IPCs in the same patients while on 
corresponding compounds, grouped based on the following compound changes: Glivec to 
Neopax (6 patients), Glivec to Imakrebin (13 patients), and Glivec to Neopax to Imakrebin, 
consecutively (5 patients). The groups were comparable by gender (p=0.546) and age 
(p=0.701). Five patients in the group whose prescriptions were refilled only with Imakrebin 
reported suboptimal adherence. Nevertheless, the difference did not reach statistical 
significance (p=0.059). Table 1 summarizes the patient’s demographics and adherence 
characteristics. 
Imatinib plasma concentrations and treatment response 
The baseline median IPC achieved with branded imatinib was 1454 µmol/L (range 485-2706) 
with 21 and 3 patients achieving major molecular response (MMR) and complete cytogenetic 
response (CCyR), respectively. Eighteen patients (75%) had IPC ≥ 1000 µmol/L. Suboptimal 
IPCs were measured in 5 patients with poor adherence. Later on, they improved compliance 
(see Table 2). Patient no. 12, who reported good adherence, had suboptimal IPCs 
regardless of the drug he was using. Since he did not meet optimal treatment goals at the 
recommended time point, imatinib dose was increased to 600 mg due to his enormous body 
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surface area. After six months, he achieved major molecular response (MMR). Eleven 
patients (10 with MMR and 1 with CCyR) were using Neopax and achieved with it median 
IPC of 1716 (1249-3630) µmol/L. All of them maintained optimal disease response while 
using Neopax. Eighteen patients, while using Imakrebin at some time point after Glivec or 
Neopax, had a median IPC 1458 (707-2880) µmol/L and maintained optimal disease 
response. Of all 24 patients, 16 (89%) had IPC ≥ 1000 µmol/L while using any of three 
compounds. 
Univariate analysis 
Achieved median IPCs with all three compounds were compared in univariate analysis. 
Although median IPC achieved with Neopax was higher, and greater inter-patient difference 
of IPCs was observed, it was statistically insignificant (p>0.257, Figure 1). Suboptimal IPCs 
were measured in 33% of patients while using Glivec, 13% of patients while using Imakrebin, 
and none while using Neopax (p=0.161, Figure 2). Suboptimal adherence was associated 
with suboptimal IPCs while using Glivec (p=0.006). The same association was not observed 
in patients while using Imakrebin (p=0.490) or Neopax (no observed suboptimal adherence 
nor IPCs). 
Six patients changed from Glivec to Neopax had a median IPC of 1821 and 1572 µmol/L, 
respectively, and no statistical difference was found (p=0.786). Comparable IPCs were 
observed in 13 patients that changed from Glivec to Imakrebin (medians 1152 vs. 1230 
µmol/L, p=0.362) and in 5 patients changing from Glivec to Neopax to Imakrebin 
consecutively (medians 1814 vs. 1717 vs. 1783 µmol/L, p>0.148). 
 
Discussion 
In our study, both imatinib generics in equivalent doses achieved adequate IPCs in most of 
the enrolled patients (100% and 89%). All patients maintained a good therapeutic response 
achieved with the branded drug. Both generics were well tolerated, and there was no 
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recorded discontinuation due to adverse effects. These results suggest comparable efficacy 
and a safety profile of examined generics to branded imatinib. Moreover, the presented data 
demonstrate interchangeability of different imatinib generics. As expected, adherence stays 
an important issue in treatment with imatinib. 
For CML patients in Croatia, imatinib is in total reimbursed by the Croatian Health Insurance 
Fund. The cost of 400 mg qd dosage of branded imatinib after generics became available, is 
now maintained between $37,200 and $31,200 per year, depending on US Dollar/Croatian 
Kuna (HRK) currency. Since the price of the first approved generic cannot cross the limit set 
at 80% of the price of the branded drug, and the price of all other generics is limited to 90% 
of the price of the first generic, by default, all generic drugs should be cheaper than the 
patented predecessor.14 The introduction of several new imatinib generics resulted in 
continuous price reductions making treatment costs as low as $12,000 annually. In the public 
health system, prescriptions for imatinib are only renewed in public hospital pharmacies that 
are supplied with it in the process of public procurement. Competing for their interests, 
pharmaceutical companies offer discounts that, in turn, lead to additional cost reductions. 
Because of that, the cost of imatinib generic can be more than five times cheaper than the 
branded imatinib. Availability of generic imatinib is expected to reduce treatment costs 
worldwide. However, its price is subject to the healthcare system organization, geopolitical 
and socioeconomic conditions of the particular country or region.15  
 
Conclusion 
Approved imatinib generics are comparable in bioavailability and efficacy with a patented 
one. Pharmacoeconomic indices are showing substantial cost reductions with significant 
savings that could be redirected to the research of new treatment modalities or treatment of 
other diseases of particular interest. All said, imatinib generics are a reasonable frontline 
therapy in CML. 
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Clinical Practice Points 
 Optimal imatinib plasma concentration (IPC ≥1000 µmol/L) correlates with a greater 
chance for optimal treatment response 
 Approved imatinib generic forms achieve comparable IPCs with branded imatinib 
 Treatment response achieved with patented imatinib was maintained while using its 
generic forms 
 Imatinib generics approved by competitive authorities are valid frontline therapy in CML 
and result in substantial treatment cost reduction 
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Figures 
Figure 1 Comparison of imatinib plasma concentrations between branded and generics 
compounds 
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Figure 2 Optimal imatinib plasma concentrations achieved with corresponding imatinib 
compound 
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Tables 
 
Table 1 Patient Demographics and Adherence Characteristics  
Parameter  
Glivec/All 
Patients  
Neopax  Imakrebin  P  
Patients While on Corresponding 
Imatinib      
Total  
    
n (%)  24 (100)  11 (46)  18 (75)  
 
Gender  
    
Male, n (%)  15 (63)  6 (55)  11 (61)  .935  
Age  
    
Median, years (range)  49 (22-76)  
49 (22-
76)  
55 (30-72)  .698  
Adherence  
    
Optimal n (%)  19 (79)  11 (100)  17 (94)  .166  
Suboptimal n (%)  5 (21)  0 (0)  1 (6)  
 
  
Parameter  
Glivec to 
Neopax  
Glivec to 
Imakrebin  
Glivec to Neopax 
then to Imakrebin  
P  
Patients Grouped According 
to Consecutive Generic Use      
Total  
    
n (%)  6 (25)  13 (54)  5 (21)  
 
Gender  
    
Male, n (%)  4 (67)  9 (69)  2 (40)  .546  
Age  
    
Median, years (range)  51 (30-67)  47 (22-76)  57 (36-72)  .701  
Adherence  
   
.059  
Optimal n (%)  6 (100)  8 (62)  5 (100)  
 
Suboptimal n (%)  0 (0)  5 (39)  0 (0)  
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Table 2  
List of Patients With Imatinib Plasma Concentrations While on Corresponding Compound and 
Disease Response  
  Gender/Age  
IPC (μmol/L) and Level of Disease Response While on Corresponding 
Imatinib 
Glivec  Neopax  Imakrebin  
1  M/40  1696  MR 3  –  
 
1230  MR 3  
2  M/67  1243  MR 4.5  1263  MR 4.5  –  
 
3  M/29  1187  MR 4  –  
 
706  MR 4  
4  M/46  1339  MR 3  1249  MR 3  –  
 
5  M/53  1152  MR 5  –  
 
1698  MR 5  
6  F/40  1814  MR 2  1410  MR 2  2034  MR 2  
7  F/50  485  MR 4.5  –  
 
1561  MR 4.5  
8  M/44  954  MR 5  –  
 
1096  MR 5  
9  M/55  1853  MR 4  1423  MR 4  –  
 
10  F/22  1853  MR 4  –  
 
1502  MR 4.5  
11  F/67  2179  MR 4  2082  MR 4.5  –  
 
12  M/62  767  CcyR  –  
 
778  CCyR  
13  M/64  1672  MR 5  –  
 
1148  MR 5  
14  M/30  1918  MR 4.5  1722  MR 4.5  –  
 
15  F/33  1788  CCyR  2351  CcyR  –  
 
16  F/72  2252  MR 5  2915  MR 5  1738  MR 5  
17  M/47  696  MR 4  –  
 
1414  MR 4.5  
18  F/36  2583  MR 4.5  3630  MR 4.5  2509  MR 4.5  
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  Gender/Age  
IPC (μmol/L) and Level of Disease Response While on Corresponding 
Imatinib 
Glivec  Neopax  Imakrebin  
19  M/57  1317  MR 4.5  1717  MR 4.5  1247  MR 4.5  
20  M/39  1569  MR 3  –  
 
1055  MR 4.5  
21  M/58  802  MR 2  –  
 
1172  MR 2  
22  F/76  2707  MR 4  –  
 
2880  MR 4  
23  M/65  1248  MR 4  1673  MR 4  1760  MR 5  
24  F/34  645  CCyR  –  
 
2239  MR 3  
Abbreviations: CCyR = Complete cytogenetic response; IPC = imatinib plasma concentration; 
MR = molecular response (as BCR-ABL1% to ABL1 on the International scale, where 10%, 1%, 
0.1%, 0.01%, 0.0032%, and 0.001% correspond to a decrease of 1, 2, 3, 4, 4.5, and 5 logs, 
respectively).  
 
